SynthesisEuropean radiology2026
Choosing wisely in neuroradiology: evaluating CT and MR utilization trends in Europe.
Synthesis in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess trends in volume and utilization of neuroimaging (CT and MR) across Europe over the last decade, within the context of evolving clinical practice on behalf of the European Society of Neuroradiology's Choosing Wisely committee. MATERIALS AND
methodsA systematic search of PubMed was performed (following PRISMA 2020 guidelines) to identify studies reporting European neuroimaging volumes. As no eligible studies were identified, descriptive analysis of Eurostat and OECD data was performed for 29 European countries from 2015 to 2022, covering CT and MR examination volumes and scanner availability per 100,000 population across four geographic regions (Northern, Southern, Eastern, and Western Europe). Total CT/MR volumes served as neuroimaging surrogates.
results316 publications were identified (with none meeting predefined inclusion criteria). Eurostat data from 29 countries revealed substantial growth in imaging from 2015 to 2022. Per capita CT exam rates increased 40.8% (10,872 to 15,312 per 100,000 population), and MR scan rates increased 43.5% (5746 to 8244 per 100,000 population). Scanner availability also increased (CT scanners from 2.3 to 2.68, MR scanners from 1.43 to 2.11 per 100,000 population). Regional variations were evident: Western Europe showed the highest utilization rates, Eastern Europe demonstrated the largest relative growth despite lower absolute numbers. All regions experienced consistent growth except during the 2020 COVID-19 disruptions.
conclusionNeuroimaging utilization has substantially increased across Europe from 2015 to 2022, with disproportionate growth in scan volumes relative to scanner availability. These findings highlight regional disparities in utilization and underscore the need for coordinated evidence-based appropriateness initiatives to support sustainable neuroimaging practice. KEY POINTS: Question Have CT and MR neuroimaging utilization rates changed across Europe over the last decade compared to scanner availability? Findings CT and MR scan rates increased 40.8% and 43.5%, respectively, from 2015 to 2022, reflecting increased per-scanner utilization across the continent. Clinical relevance Neuroimaging examination volumes increased substantially across Europe from 2015 to 2022. This highlights the value of evidence-based imaging appropriateness initiatives to ensure sustainable healthcare resource utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.